Basilar Artery Occlusion: Clinical Management and Therapy by Sparaco, Marco
Clinical Management Issues
67
1% to 4% of all ischemic strokes [3]. BAO 
still represents one of the most challenging 
conditions to diagnose and manage. De-
spite better imaging techniques, in fact, the 
diagnosis of this condition is often delayed, 
especially because in many cases presenting 
symptoms are non-focal, such as headache, 
dizziness, and vertigo [1-3]. The aim of this 
article is to provide clinicians with an easy 
and reliable tool for promptly recognizing 
and treating BAO.
EtIology
The most frequent causes of BAO are local 
thrombosis and artery-to-artery thrombo-
embolism originating from arteriosclerotic 
lesions [3]. Other important etiologies are 
cardiac emboli and vertebral artery dissec-
IntroduCtIon
The vertebrobasilar arterial system receives 
only 20% of cerebral blood flow and supplies 
the posterior portion of the brain including 
the brainstem, the thalami, the cerebellum, 
and parts of the occipital and temporal lobes 
[1,2]. Posterior circulation ischemia (PCI) is 
a clinico-pathological condition associated 
with an infarction within the vertebrobasi-
lar arterial system and is characterized by a 
complex symptomatology, course, and out-
come [1,2]. PCI accounts for about 20-25% 
of all ischemic strokes and has an adjusted 
incidence of 18 per 100.000 person-years 
(95% confidence interval—CI: 10/100,000 
to 26/100,000) [1,2]. Basilar artery occlu-
sion (BAO) is a potentially life-threatening 
subset of PCI, carrying > 80% fatality rate 
without treatment and accounts for about 
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Abstract
Basilar artery occlusion is a potentially life-threatening subset of the larger category of posterior 
circulation strokes, carrying > 80% fatality rate without treatment. This condition accounts 
for about 1% to 4% of all ischemic strokes and is generally related to local atherothrombosis or 
cardioembolism.
Diagnosis can be challenging because presenting symptoms are often non focal, such as headache, 
dizziness, and vertigo. The onset of the symptomatology can be abrupt without preceding events, 
abrupt with prodromal symptoms, or progressive and stuttering. Finally, the severity of clinical 
presentation may range from isolated cranial nerve palsies to tetraplegia, locked-in state, or coma.
If basilar artery occlusion is readily recognized and confirmed with the aid of neuroimaging, 
intravenous thrombolysis or endovascular treatment can be undertaken immediately in order 
to recanalize the occluded artery and thus reduce mortality and improve outcome.
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caused by irritation of trigeminovascular af-
ferents located in brainstem [12]. In a study 
by Ferbert et al. of 85 patients with BAO, 
headache was reported in 25.8% of cases on 
admission [8]. The headache occurred during 
the 2 weeks before the stroke and had a pre-
dominantly occipital localization. The onset 
was both sudden and the main complaint, so 
that initially it was considered subarachnoid 
hemorrhage [8].
the onset of symptomatology is quite 
variable
Based on the symptoms onset, three ma-
jor clinical types of BAO presentation have 
been described [3,13]:
 y Abrupt without preceding events. This 
form is characterized by sudden onset 
of severe motor and bulbar symptoms 
(i.e. quadriplegia, ophthalmoplegia, and 
anarthria) combined with reduced con-
sciousness.
 y Abrupt with prodromal symptoms. 
Transient prodromal symptoms, such as 
double vision, dysarthria, vertigo, par-
esthesiae, etc., precede the monophasic 
BAO symptoms by several days or even 
months.
 y Progressive and stuttering. This form 
is characterized by gradual or stuttering 
course of posterior circulation symptoms 
such as blurred vision, balance disturbance, 
dysarthria, bilateral paresthesiae, or mo-
tor weakness, which finally are associated 
with a reduced consciousness [3,13].
the clinical picture varies depending on 
the site and type of the BA obstruction
Owing to different degrees of the brain-
stem involvement, the severity of the clinical 
presentation may range from isolated cranial 
nerve palsies to tetraplegia, locked-in state, 
or coma [3].
 y Occlusions of the proximal or middle 
segments of the BA usually cause large 
pontine strokes with quadriplegia, reduced 
consciousness, dysarthria and dysphagia, 
horizontal gaze paresis, and other cranial 
nerve palsies [3].
 y Occlusions in the distal segment of the 
BA result in strokes bilaterally in the mes-
encephalon and thalamus with decreased 
consciousness, quadriparesis, and nuclear 
or supranuclear oculomotor and pupillo-
motor dysfunctions [3].
tions, affecting respectively 30-35% and 
6-8% of patients [3]. Atherosclerosis pref-
erentially involves the proximal and middle 
segments of the basilar artery (BA), while 
the occlusion of the distal segment is typi-
cally indicative of an arterioembolic or car-
dioembolic event [3-5].
Vertebrobasilar dolichoectasia, an ana-
tomic variant consisting of enlargement 
and dilatation of the vertebral/basilar artery, 
has been shown also to predispose to BAO 
through a reduction in flow velocity leading 
to local thrombus formation [1,6].
Rare causes include arteritis, meningitis, 
cervical trauma, coagulopathy, aneurysms, 
hereditary arteriopathies, as well as compli-
cations after endovascular procedures and 
neurosurgery [3].
Finally, we recently described a case of 
reversible stenosis of the BA due to hemo-
concentration, a condition frequently found 
in psychiatric patients, especially if suffering 
from a severe depression [7].
ClInICAl FEAturEs
Several aspects, described hereafter, con-
tribute to make BAO one of the most chal-
lenging conditions to diagnose and manage:
Presenting symptoms are often non‑focal
Most common premonitory symptoms of 
BAO are dizziness and vertigo, followed by 
headache and neck pain [3,8,9].
Dizziness and vertigo are two terms used 
interchangeably by patients to indicate non-
specific symptoms accounting for about 4 
million emergency department visits annu-
ally in the United States [9]. Dizziness is 
usually described as a feeling of light-head-
edness or lack of mental clarity [10]. Vertigo 
more specifically describes a sensation of 
spinning and usually indicates dysfunction 
of the peripheral vestibular or central ves-
tibule-cerebellar system [6]. Vertigo and/or 
dizziness caused by BAO are usually associ-
ated to other brainstem or cerebellar symp-
toms [6]. However, when vertigo is the only 
symptom and the neurologic examination 
is normal is not easy to establish the central 
or peripheral origin of the symptomatology. 
In these cases the head-impulse-nystag-
mus-test of skew (HINTS) can be a useful 
bedside test to distinguish between vertigo 
caused by peripheral or central lesions [11].
In patients with PCI headache is a com-
mon presenting symptom that seems to be 
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This rare type of primary headache disorder, 
previously referred to as basilar migraine, is 
characterized by attacks preceded and/or 
accompanied by transitory focal neurologic 
symptoms pointing to dysfunction in the 
region supplied by the BA and its branches 
[18]. The diagnosis is based on the finding 
of at least two migraine attacks accompa-
nied by at least two of the following fully 
reversible symptoms: dysarthria, vertigo, 
tinnitus, impaired hearing, double vision, 
ataxia, and decreased level of conscious-
ness [18,19].
InvEstIgAtIon
Computed tomography (CT), contrast-
enhanced CT angiography (CTA), MRI, 
magnetic resonance angiography (MRA), 
and Doppler sonography can be used in the 
acute setting to evaluate patients with sus-
pected BAO. If a patient is a candidate for 
thrombolytic therapy, neuroimaging should 
be performed as soon as possible to reduce 
the door to needle time.
 y Non-contrast CT (NCCT) is essential 
to quickly rule out hemorrhagic stroke 
and other intracranial space occupying 
lesions. The pc-Alberta stroke program 
early CT score (pc-ASPECTS) measur-
ing early ischemic changes in 8 different 
brain regions has been recently proposed 
as a grading system to evaluate stroke ex-
tension and predict outcome in PCI [20]. 
Unfortunately, in PCI beam hardening 
due to the skull base, reduces CT sensi-
tivity, and stroke could be identified in 
the acute phase only in around 20-40% 
of patients [21]. A dense basilar artery 
sign is visible in only about two-thirds 
of patients, but, when present, it is highly 
specific for BAO [3]. Contrast-enhanced 
CT angiography (CTA) has great value 
to detect vascular occlusions and is in-
creasingly used in comprehensive stroke 
centers to select candidates for endovas-
cular treatment. Currently, great atten-
tion is given to the prognostic value of 
collateral blood flow in the hyperacute 
phase of stroke. Recently, two semiquan-
titative CTA-based grading systems have 
been proposed to quantify the potential 
collateral flow in patients with acute 
BAO: the posterior circulation collateral 
score (PC-CS) and the basilar artery on 
Computed Tomography angiography 
(BATMAN) score [22,23]. Both of these 
 y The disorder known as “top of the basi-
lar syndrome” is characterized by visual, 
oculomotor, and behavioral abnormalities 
(i.e. somnolence, vivid hallucinations, and 
dreamlike behavior), often without sub-
stantial motor dysfunction [14,15].
 y Large pontine strokes resulting from BAO 
are the most frequent cause of locked-in 
syndrome, a disorder characterized by 
quadriplegia, bilateral facial plegia, anar-
thria, and aphagia [3]. The typical involve-
ment of pontine tegmentum is responsible 
for horizontal gaze paresis. Patients, that 
are awake and alert, can communicate 
just by blinking and vertical eye move-
ments [3].
dIFFErEntIAl dIAgnosIs
Any rapidly progressive clinical condition 
with multiple cranial nerve dysfunctions 
(i.e. cranial polyradiculitis, Miller-Fisher 
syndrome, botulism, or myasthenic crisis) 
can potentially be mistaken for a brainstem 
lesion.
Toxic or metabolic disturbances, such as 
drug abuse or hypoglycemia, may initially 
present with features resembling cerebro-
vascular disease. Central pontine myelinoly-
sis and Wernicke’s encephalopathy usually 
present with brainstem deficits. A history of 
rapid correction of hyponatremia or of poor 
nutritional intake will clarify the diagnosis.
Neuroinflammatory disorders, such as 
sarcoidosis or Behçet’s disease, may acutely 
affect the brainstem. However, these diseases 
often have systemic clinical features which 
are useful for correctly guiding the diagnosis.
Central nervous system (CNS) infection 
by viruses (i.e. Epstein-Barr virus or West 
Nile virus), bacteria (i.e., Listeria monocy-
togenes), or fungi may mimic stroke [16]. 
Clinical findings, cerebrospinal fluid ex-
amination, and magnetic resonance imaging 
(MRI) features usually help to get a correct 
diagnosis.
Acute intracranial hemorrhage affecting 
brainstem, subarachnoid hemorrhage, and 
tumor mimicking ischemic stroke can be dif-
ferentiated from BAO only by imaging [16].
Extensor jerks and spasms and decerebrate 
posturing arising with BAO are sometimes 
mistaken for grand mal seizures [17].
Finally, in the presence of a headache 
associated with posterior circulation symp-
toms, a clinician should also consider the 
diagnosis of a migraine with brainstem aura. 
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ACutE trEAtMEnt
Acute BAO treatment aims to restore the 
cerebral blood flow in the occluded vessel 
and salvage brain tissue. It has been shown 
that BA recanalization can substantially 
enhance a patient’s chances of survival and 
of good functional recovery [3]. A meta-
analysis of 45 studies (n = 2056) on acute 
BAO, in particular, has shown that recanali-
zation of BA results in a two-fold reduction 
in mortality and 1.5-fold reduction in death 
or dependency [32].
Furthermore, the existence of a relation-
ship between the time from symptom on-
set to arterial recanalization and clinical 
outcome has been widely demonstrated. As 
evidenced in the BASICS registry, a sig-
nificantly increased risk of poor outcome 
seems to occur when recanalization therapy 
is started > 6 hours after the estimated time 
of BAO [33]. In this regard, it is necessary to 
clarify the concept of “time to recanalization 
therapy”, i.e. the interval between estimated 
time of BAO and start of recanalization 
therapy. Since BAO is preceded by prodro-
mal symptoms in > 60% of cases [3,34,35], 
most of these patients are likely to be ex-
cluded from any acute therapeutic option if 
it is considered as an inclusion criterion the 
time of onset of any symptom to treatment. 
Therefore, as suggested in the BASICS reg-
istry, the estimated time of BAO is defined as 
“time of onset of acute symptoms leading to 
clinical diagnosis of BAO or, if not known, 
last time the patient was seen normal before 
onset of these symptoms” [33].
Acute treatment options for BAO include 
intravenous fibrinolysis (IVT), intra-arterial 
thrombolysis (IAT), and/or endovascular 
mechanical treatment [1-3,23].
 y IVT. It is the first therapeutic strategy 
introduced for the management of acute 
ischemic stroke. This treatment was first 
evaluated in several randomized con-
trolled trials (RCTs) with recombinant 
tissue plasminogen activator (rt-PA), 
such as NINDS, ECASS, ECASS II, 
and ATLANTIS [36-39]. In particu-
lar, the NINDS study found a benefit of 
IVT when treatment was started within 
three hours of the onset of symptoms and 
demonstrated that patients treated with 
rt-PA were at least 30% more likely to 
have a good functional outcome than pa-
tients treated with placebo [36]. The safety 
and efficacy of IVT were then evaluated 
in three multicenter studies, that are the 
scores proved to be strong predictors of 
functional outcome as well as mortality 
in BAO and can help to select patients 
for endovascular treatment [22,23]. CT 
whole brain volume perfusion (PCT) 
measures changes in Hounsfield unit 
values per pixel over time after contrast 
injection, providing information about 
capillary-level hemodynamics of brain 
parenchyma. PCT allows to measure 
parameters such as mean transit time 
(MTT), time to peak (TTP), cerebral 
blood flow (CBF), and cerebral blood 
volume (CBV) [24]. A mismatch be-
tween a hypoperfused area (reduced CBF 
and increased MTT and TTP) and the 
ischemic core (reduced CBV) may entail 
the presence of the so-called ischemic 
penumbra—hypoperfused still viable 
parenchyma. Therefore, PCT has been 
used to select patients with strokes with 
salvageable tissue, eligible for endovascu-
lar treatment also outside common time 
windows [25-27]. Using multimodal CT, 
encompassing NCCT, CTA and PCT, 
vertebrobasilar strokes were diagnosed in 
the acute phase in up to 76% of patients. 
Sensitivity for pons/midbrain lesion was 
around 60% [28,29].
 y MRI is more sensitive than CT in the as-
sessment of PC infarcts, particularly in the 
brainstem, and can detect early evidence 
of infarction with diffusion-weighted im-
aging (DWI) sequences [1,2,30]. MRI-
DWI is considered the gold standard to 
evaluate infarct core [31]. MRI-perfusion 
weighted imaging (PWI), likewise PCT, 
can define the hypoperfused brain area 
during ischemic stroke. MRI diffusion-
perfusion mismatch may be helpful to 
select patients for acute recanalization 
therapies [31]. MRA allows, even with-
out contrast injection, to identify the type 
and location of BA occlusion or stenosis.
 y Angiography is still the gold standard for 
collateral evaluation in BAO and is used in 
the hyperacute phase only for therapeutic 
purposes [1,3,9].
 y Transcranial echo-color-Doppler can 
show intracranial vascular occlusions 
[2,30]. However, ultrasound investiga-
tion is more operator-dependent and less 
sensitive in the diagnosis of posterior cir-
culation disease than MRA or CTA, and 
can be rarely used as the sole or primary 
investigation for the assessment of PC 
strokes [1,30].
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different types of devices. Currently, the 
so-called “stent retrievers” are the most 
commonly used ones. These new devices 
can be deployed within the clot, quickly 
removing the clot and restoring the blood 
flow once retrieved. Compared to previ-
ous treatments, MT methods reach higher 
recanalization rates and have lower risk 
of hemorrhages and wider time window 
[45,47]. Recently, an observational, mul-
ticenter study, including 148 consecutive 
patients with BAO treated with endovas-
cular procedures, the ENDOSTROKE 
study, reported a good outcome (mRS 
0-2) in up to 34% of treated patients, irre-
spectively of stroke severity, and complete 
recanalization in 79% of cases [48]. More 
recently, Gory and colleagues analyzed 22 
consecutive patients with basilar stroke 
treated at their hospital with SolitaireTM 
stent-retrievers and performed a system-
atic review of published data (15 studies 
involving a total of 312 subjects). The re-
canalization rate reached 81% (95% CI: 
73% to 87%), good outcome was found in 
42% (95% CI: 36% to 48%), and symp-
tomatic intracranial hemorrhage was 
observed in 4% (95% CI: 2% to 8%) of 
cases [49].
Over the past decade, treatment for acute 
ischemic stroke has evolved to include both 
IVT and endovascular procedures. Phan et 
al. analyzed six randomized controlled trials 
involving 1943 patients to assess the func-
tional outcomes and complications of IVT 
with and without endovascular treatment. In 
this study, patients who received IVT with 
endovascular treatment had significantly 
higher rates of excellent functional outcomes 
(mRS 0-1) (95% CI: 1.29-2.39; RR: 1.75) 
in comparison with those who received IVT 
alone. Endovascular treatment increased the 
RR of a good functional outcome by at least 
30% compared to IVT alone [50].
Perfect timing for endovascular treatment 
in BAO is not well established. Recently, 
published American guidelines suggest to 
perform MT in PCI only within 6 hours 
from stroke onset [51]. However, most cen-
ters, considering the poor prognosis associ-
ated with BAO, apply recanalization thera-
pies for this pathology up to 12-24 hours 
after symptom onset [52].
An analysis of 19 published cohorts of pa-
tients with BAO showed that higher recana-
lization rates, such as those obtained with 
endovascular mechanical treatments, de-
crease mortality but do not necessarily trans-
SITS-MOST, the ECAS III, and the 
IST-3, with a therapeutic window of 3, 
4.5, and 6 hours, respectively [40-42]. 
However, the vast majority of data from 
these studies concern patients with an-
terior circulation infarcts (ACI). Indeed, 
data regarding PC strokes in the SITS-
MOST and ECASS III studies are lack-
ing and only 8.1% of patients included 
in the IST-3 trial had PCI [42]. In the 
last years, several trials performed with 
angiographic assessment have reported a 
progressive improvement of the recana-
lization rate and functional outcome in 
patients with BAO treated with IV rtPA. 
In a Finnish single-center consecutive 
IVT series the rate of recanalization was 
65% and 30 of 116 patients (26%) had 
good outcome (modified Rankin Scale 
[mRS] 0-2) by 3 months [43]. A study 
by Strbian et al. on 184 patients with 
angiography-proven BAO treated with 
IVT showed that recanalization of BAO 
produced good outcomes in 50% of pa-
tients without extensive baseline ischemia 
(pc-ASPECT ≥ 8) [44].
 y IAT. Findings from uncontrolled and 
controlled studies with IAT have shown a 
high recanalization rate, ranging on aver-
age from 63% to 65% [13,45]. The results 
of an analysis of 420 non-randomized pa-
tients with BAO treated with IAT (82%) 
or with IVT (18%) showed not significant 
differences between the two groups of pa-
tients in death, dependency, and favorable 
outcomes, although the recanalization rate 
was higher in patients treated with IAT 
(65% vs. 53%) [13]. The Basilar Artery In-
ternational Cooperation Study (BASICS), 
a prospective, observational study of pa-
tients with BAO, compared efficacy of 
antithrombotic treatment, IVT and IAT 
[46]. In patients with mild-to-moderate 
basilar stroke, a good outcome (mRS 0-2) 
was achieved in higher proportion in the 
IV thrombolysis group compared to in-
tra-arterial treatment group (respectively 
53% vs. 30%). Outcome did not differ 
significantly when considering patients 
with severe stroke (mRS ≤ 2 in 20% vs. 
11%). Recanalization occurred in 72% of 
patients treated with endovascular proce-
dures compared to 63% of patients treated 
with IV thrombolysis and was associated 
with increased independency [46].
 y Endovascular mechanical treatment. In 
the last years, mechanical thrombectomy 
(MT) has been performed using many 
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Patients should be placed on continu-
ous cardiac monitoring to detect cardiac 
arrhythmias (i.e. atrial fibrillation, etc.) 
and to check the blood pressure. Patients 
with BAO may be particularly sensitive to 
changes in blood pressure [9]. However, so 
far the balance of risk and benefit in lower-
ing blood pressure in these cases is not yet 
clear. In a study that analyzed the associa-
tion between blood pressure and stroke in 
patients undergoing endarterectomy for 
symptomatic carotid stenosis it was found 
higher risk of stroke at lower blood pressure, 
especially if systolic blood pressure <  140 
mmHg [54]. There are no similar studies in 
patients with BAO, but the same possibil-
ity of hemodynamic insufficiency at lower 
blood pressures exists. Therefore, caution is 
advised in lowering the pressure aggressively 
in these patients, particularly if they have 
limited or absent posterior communicating 
arteries as well as other collateral flow ab-
normalities [1].
The choice of the appropriate medical 
therapy for secondary prevention of BAO 
should be based on the causative stroke 
mechanism (i.e. cardioembolic, athero-
sclerotic, etc.) as well as on the risk strati-
fication for recurrence [1-3,30]. Therefore, 
possible medical treatments include anti-
platelet agents or anticoagulants, as well 
as lipid-lowering drugs. Recommended 
treatment is detailed in recent guidelines 
[51,55]. In patients with indications for an-
ticoagulation (i.e. atrial fibrillation), treat-
ment should be started generally within 
two weeks after an acute ischemic stroke, 
to avoid the risk of hemorrhagic transfor-
mation of the infarct.
Key points
 y BAO is a potentially life-threatening neurologic emergency that requires high suspicion index
 y Patients presenting with sudden onset of headache or vertigo need an accurate neurologi-
cal and neuroradiological evaluation
 y Multimodal CT (if available) or MRI must be promptly used in the acute setting to con-
firm the diagnosis of BAO
 y As soon as BAO is confirmed with neuroimaging, intravenous thrombolysis or endovas-
cular treatment can be undertaken
 y Shortening the time from the symptoms onset to start of the treatment can give patients 
better chance to survive and avoid severe complications
 y Identification causes of BAO is essential for choosing the most appropriate secondary medi-
cal therapy
 y Screening of uncommon causes of BAO is mandatory
 y MRI is a gold standard for follow up of BAO
late into better outcomes [3,53]. Therefore, 
even if it is widely agreed that significant 
survival after BAO requires rapid access to 
revascularization, straightforward evidence 
about efficacy of endovascular therapy (i.e. 
IAT or MT) over systemic fibrinolysis in 
basilar stroke is still missing [53].
In‑HosPItAl MAnAgEMEnt And 
sECondAry PrEvEntIon
Patients with BAO should be carefully 
monitored with MRI to evaluate burden 
lesion and cerebellar edema. The latter gen-
erally peaks 3 to 5 days after infarction and 
may cause compression of the fourth ven-
tricle and/or herniation [9]. After initial 
stabilization, patients should undergo an 
extensive systematic etiological work-up 
including the following assessments:
 y Laboratory testing: complete blood count, 
fasting lipids, C-reactive protein, erythro-
cyte sedimentation rate, coagulation panel, 
antiphospholipid and/or anticardiolipin 
antibodies, lupus anticoagulant, and gly-
cated hemoglobin A1c;
 y Genetic analysis focusing on inherited 
prothrombotic states: factor V Leiden/
G1691A, prothrombin/G20210A, etc.;
 y MRA (or CTA) and ultrasound investiga-
tion of the head and neck: to evaluate for 
atherosclerotic disease, dissection, verte-
brobasilar dolichoectasia, luminal narrow-
ing, or occlusion;
 y Echocardiogram: to evaluate for potential 
cardiac sources of emboli such as a valvu-
lar vegetation, ventricular thrombus, etc.
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ProPosEd AlgorItHM For ACutE BAo MAnAgEMEnt
BAO = basilar artery occlusion; CT = computed tomography; CTA = computed tomography angiography; MRA = magnetic 
resonance angiography; MRI = magnetic resonance imaging
*“Time of onset of acute symptoms leading to clinical diagnosis of BAO or, if not known, last time the patient was seen 
normal before onset of these symptoms” [33].
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